Jivolar (Metformin Hydrochloride, Sitagliptin)

Metformin lowers glucose production by the liver and increases insulin sensitivity in muscle and fat tissue. Sitagliptin blocks the enzyme DPP‑4, prolonging the action of incretin hormones (GLP‑1 and GIP) that stimulate insulin release and suppress glucagon, thereby reducing blood glucose levels.

The dose of Jivolar is individualized by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and response to therapy. The prescriber determines the appropriate strength and dosing schedule; patients should follow the written prescription exactly.

Safety of Jivolar during pregnancy and lactation has not been established. Because metformin and sitagliptin cross the placenta and are excreted in breast milk, the product is generally avoided unless the potential benefit justifies the potential risk. Consultation with a healthcare provider is essential.

To request Jivolar, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Jivolar offers a fixed‑dose combination of metformin and sitagliptin, providing both insulin‑sensitising and incretin‑enhancing effects in a single tablet. Compared with metformin alone, it yields greater HbA1c reduction, and versus sitagliptin alone, it adds the benefits of reduced hepatic glucose output. This dual approach can simplify regimens and improve adherence relative to taking separate agents.

Jivolar tablets should be stored at ambient temperature, preferably below 25 °C. Keep the medication in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed when not in use.

Jivolar is taken orally, usually with meals to reduce gastrointestinal discomfort. The tablets are swallowed whole with a glass of water. Patients should follow the dosing instructions provided by their prescriber and not crush or split the tablets unless specifically advised.

The most serious adverse events include lactic acidosis, which is rare but life‑threatening, and severe hypoglycaemia, especially when used with insulin or sulfonylureas. Signs of pancreatitis, such as persistent abdominal pain, and severe skin reactions like Stevens‑Johnson syndrome also require immediate medical attention.

Jivolar is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), known hypersensitivity to metformin or sitagliptin, and those with a history of lactic acidosis. It should also be avoided in individuals with acute or chronic metabolic acidosis, including diabetic ketoacidosis.